TAS-102 in patients with metastatic colorectal cancer refractory to standard therapies including regorafenib

被引：0

作者：

Kito, Yosuke ^{[1
]}

Hamauchi, Satoshi ^{[1
]}

Yamazaki, Kentaro ^{[1
]}

Komori, Azusa ^{[2
]}

Masuishi, Toshiki ^{[2
]}

Taniguchi, Hiroya ^{[2
]}

Mori, Keita ^{[3
]}

Muro, Kei ^{[2
]}

Yasui, Hirofumi ^{[1
]}

机构：

[1] Shizuoka Canc Ctr, Div Gastrointestinal Oncol, Nagaizumi, Shizuoka, Japan

[2] Aichi Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Aichi, Japan

[3] Shizuoka Canc Ctr, Clin Res Ctr, Nagaizumi, Shizuoka, Japan

来源：

ANNALS OF ONCOLOGY | 2016年 / 27卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

O1 - 8 - 3

引用

页数：1

共 50 条

[21] Hospitalizations and Clinical Outcome in Metastatic Colorectal Cancer During Regorafenib or TAS-102 Therapy
Huemer, Florian
Piringer, Gudrun
Schlintl, Verena
Hackl, Hubert
Rinnerthaler, Gabriel
Thaler, Josef
Greil, Richard
Weiss, Lukas
CANCERS, 2020, 12 (10) : 1 - 11
[22] Regorafenib, TAS-102, or fruquintinib for metastatic colorectal cancer: any difference in randomized trials?
Zhang, Qi
Wang, Qianqian
Wang, Xicheng
Li, Jian
Shen, Lin
Peng, Zhi
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2020, 35 (02) : 295 - 306
[23] TAS-102 for the treatment of metastatic colorectal cancer
Salvatore, Lisa
Rossini, Daniele
Moretto, Roberto
Cremolini, Chiara
Schirripa, Marta
Antoniotti, Carlotta
Marmorino, Federica
Loupakis, Fotios
Falcone, Alfredo
Masi, Gianluca
EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (11) : 1283 - 1292
[24] Comparison of skeletal muscle mass loss in patients with metastatic colorectal cancer treated with regorafenib or TAS-102
Hacioglu, Muhammet Bekir
Kostek, Osman
Kurt, Nazmi
Kucukarda, Ahmet
Gokyer, Ali
Ustabasioglu, Fethi Emre
Karatas, Fatih
Tuncbilek, Nermin
Uzunoglu, Sernaz
Bilici, Ahmet
Cicin, Irfan
Erdogan, Bulent
JOURNAL OF BUON, 2019, 24 (05): : 2198 - 2204
[25] Sidedness of the primary tumor on the effect of TAS-102 for refractory metastatic colorectal cancer
Ueda, S.
Tsuboguchi, Y.
Nakatani, Y.
Tsuya, A.
Nishina, S-I.
Akiyoshi, K.
Okazaki, S.
Tokunaga, S.
Daga, H.
ANNALS OF ONCOLOGY, 2018, 29
[26] Tas-102 for Refractory Metastatic Colorectal Cancer: A Multicenter Retrospective Cohort Study
Conti, Matteo
Bolzacchini, Elena
Luchena, Giovanna
Bertu', Lorenza
Tagliabue, Paola
Aglione, Stefania
Ardizzoia, Antonio
Arnoffi, Jessica
Guida, Francesco Maria
Bertolini, Alessandro
Pastorini, Alessandro
Duro, Maria
Bettega, Donato
Roda', Giovambattista
Artale, Salvatore
Squizzato, Alessandro
Giordano, Monica
CANCERS, 2023, 15 (13)
[27] A phase II study of guadecitabine combined with irinotecan vs regorafenib or TAS-102 in irinotecan-refractory metastatic colorectal cancer patients
Lee, Valerie
Parkinson, Rose
Zahurak, Marianna
Cope, Leslie
Cercek, Andrea
Verheul, Henk
Gootjes, Elske
Lenz, Heinz Josef
Iqbal, Syma
Jones, Peter
Baylin, Stephen
Rami, Vandna
Ahuja, Nita
El Khoueiry, Anthony
Azad, Nilofer S.
INTERNATIONAL JOURNAL OF CANCER, 2024, 154 (10) : 1794 - 1801
[28] Regorafenib Is Associated With Increased Skeletal Muscle Loss Compared to TAS-102 in Metastatic Colorectal Cancer
Huemer, Florian
Schlintl, Verena
Hecht, Stefan
Hackl, Hubert
Melchardt, Thomas
Rinnerthaler, Gabriel
Greil, Richard
Weiss, Lukas
CLINICAL COLORECTAL CANCER, 2019, 18 (02) : 159 - +
[29] Erratum to: Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer
Johanna C. Bendell
Lee S. Rosen
Robert J. Mayer
Jonathan W. Goldman
Jeffrey R. Infante
Fabio Benedetti
Donghu Lin
Hirokazu Mizuguchi
Christopher Zergebel
Manish R. Patel
Cancer Chemotherapy and Pharmacology, 2016, 77 : 439 - 439
[30] Colorectal Cancer TAS-102 effective with refractory Recurrence
Franke, Katharina
ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2015, 53 (10): : 1144 - 1144

← 1 2 3 4 5 →